CJC1295 is a synthetic growth hormone-releasing (GHRH) peptide that is comprised of 30 amino acids. The Sequence of CJC 1295 is : Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala- Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys.

It is recognized as the most effective GHRH used for growth hormone optimization. It can be combined (stacked) with other peptides, such as Ipamorelin, for a powerful synergistic effect. It is often included in an HRT program to manage aging and a TRT program for enhanced performance. CJC1295 has demonstrated the ability to increase fat loss and bolster muscle mass while enabling the body to more efficiently synthesize protein. In addition to steadily maximizing GH production, CJC1295 also increases insulin-like growth factor 1 (IGF-1) secretion. Primarily secreted by the liver, IGF-1 is an anabolic hormone that helps promote human growth throughout the entire body, particularly skeletal muscle. IGF-1 also aids in bone density and kidney filtration. One of the key advantages of CJC1295 is that it does not increase the production of potentially contraindicated hormones such as prolactin. CJC1295 is usually administered via subcutaneous injection.

The combination of CJC1295 and Ipamorelin has been developed because the two can act together on the pituitary and hypothalamus to increase levels of growth hormone in your body. It is done in this way to maximize the amount of growth hormone being released into your body for therapeutic benefit while acting on two separate families of receptors.

Common side effects of CJC1295/Ipamorelin include reactions at the injection site, such as pain, redness, or swelling, along with flushing of the face; less than 1 percent of patients report dizziness, headache, or hyperactivity.